dc.contributor.authorReza, Musarrat Maisha
dc.contributor.authorSim, Chu Ming
dc.contributor.authorSubramaniyam, Nathiya
dc.contributor.authorGe, Xiaojia
dc.contributor.authorSharma, Mridula
dc.contributor.authorKambadur, Ravi
dc.contributor.authorMcFarlane, Craig
dc.date.accessioned2018-03-27T07:58:15Z
dc.date.available2018-03-27T07:58:15Z
dc.date.issued2017
dc.identifier.citationReza, M. M., Sim, C. M., Subramaniyam, N., Ge, X., Sharma, M., Kambadur, R., & McFarlane, C. (2017). Irisin treatment improves healing of dystrophic skeletal muscle. Oncotarget, 8(58), 98553-98566.en_US
dc.identifier.urihttp://hdl.handle.net/10220/44623
dc.description.abstractBackground: Irisin is an exercise induced myokine that is shown to promote browning of adipose tissue and hence, increase energy expenditure. Furthermore, our unpublished results indicate that Irisin improves myogenic differentiation and induces skeletal muscle hypertrophy. Since exercise induced skeletal muscle hypertrophy improves muscle strength, we wanted to investigate if ectopic injection of Irisin peptide improves skeletal muscle function in a mouse model of muscular dystrophy. This utility of Irisin peptide is yet to be studied in animal models. Methods: In order to test this hypothesis, we expressed and purified recombinant murine Irisin peptide from E. coli. Three- to six-week-old male mdx mice were injected IP with either vehicle (dialysis buffer) or Irisin recombinant peptide for two or four weeks, three times-a-week. Results: Irisin injection increased muscle weights and enhanced grip strength in mdx mice. Improved muscle strength can be attributed to the significant hypertrophy observed in the Irisin injected mdx mice. Moreover, Irisin treatment resulted in reduced accumulation of fibrotic tissue and myofiber necrosis in mdx mice. In addition, Irisin improved sarcolemmal stability, which is severely compromised in mdx mice. Conclusion: Irisin injection induced skeletal muscle hypertrophy, improved muscle strength and reduced necrosis and fibrotic tissue in a murine dystrophy model. These results demonstrate the potential therapeutic value of Irisin in muscular dystrophy.en_US
dc.description.sponsorshipASTAR (Agency for Sci., Tech. and Research, S’pore)en_US
dc.description.sponsorshipNMRC (Natl Medical Research Council, S’pore)en_US
dc.format.extent14 p.en_US
dc.language.isoenen_US
dc.relation.ispartofseriesOncotargeten_US
dc.rights© 2017 Reza et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en_US
dc.subjectSkeletal Muscleen_US
dc.subjectDystrophyen_US
dc.titleIrisin treatment improves healing of dystrophic skeletal muscleen_US
dc.typeJournal Article
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.identifier.doihttp://dx.doi.org/10.18632/oncotarget.21636
dc.description.versionPublished versionen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record